Todays Report: Today, 1,250 Shares of ChemoCentryx Inc. (CCXI) Stock are sold by Petrus Bekker

Today, 1,250 Shares of ChemoCentryx Inc. (CCXI) Stock are sold by Petrus Bekker

ChemoCentryx Inc. (NASDAQ:CCXI) insider Petrus Bekker sold 1,250 shares of the stock in a transaction that occurred on Tuesday, November 22nd. The stock was sold at an average price of $8.30, for a total transaction of $10,375.00. Following the completion of the transaction, the insider now owns 54,844 shares in the company, valued at approximately $455,205.20. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Petrus Bekker also recently made the following trade(s): On Friday, November 11th, Petrus Bekker sold 33,332 shares of ChemoCentryx stock. The stock was sold at an average price of $8.00, for a total transaction of $266,656.00.

Shares of ChemoCentryx Inc. (NASDAQ:CCXI) opened at 7.87 on Friday. The company’s market cap is $376.23 million. ChemoCentryx Inc. has a 1-year low of $1.92 and a 1-year high of $8.37. The firm’s 50-day moving average is $6.70 and its 200-day moving average is $5.22.

Several large investors have recently modified their holdings of CCXI. BlackRock Fund Advisors raised its stake in shares of ChemoCentryx by 9.3% in the third quarter. BlackRock Fund Advisors now owns 1,267,682 shares of the biopharmaceutical company’s stock worth $7,657,000 after buying an additional 107,535 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of ChemoCentryx by 6.4% in the second quarter. Vanguard Group Inc. now owns 1,083,075 shares of the biopharmaceutical company’s stock worth $4,863,000 after buying an additional 65,013 shares during the last quarter. Oxford Asset Management acquired a new stake in shares of ChemoCentryx during the second quarter worth $2,409,000. Nantahala Capital Management LLC raised its stake in shares of ChemoCentryx by 8.8% in the third quarter. Nantahala Capital Management LLC now owns 466,440 shares of the biopharmaceutical company’s stock worth $2,817,000 after buying an additional 37,753 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. raised its stake in shares of ChemoCentryx by 9.2% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 375,965 shares of the biopharmaceutical company’s stock worth $2,271,000 after buying an additional 31,731 shares during the last quarter. Institutional investors and hedge funds own 48.09% of the company’s stock.

Several brokerages have recently weighed in on CCXI. Zacks Investment Research upgraded shares of ChemoCentryx from a “hold” rating to a “buy” rating and set a $9.00 price objective on the stock in a research note on Monday. JPMorgan Chase & Co. restated a “buy” rating and set a $11.00 target price on shares of ChemoCentryx in a research note on Tuesday, August 9th.

About ChemoCentryx

Related posts

Leave a Comment